Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea

被引:3
|
作者
Lee, Byung-Hyun [1 ]
Moon, Hyemi [2 ]
Chae, Jae-Eun [2 ]
Kang, Ka-Won [1 ]
Kim, Byung-Soo [1 ]
Lee, Juneyoung [2 ]
Park, Yong [1 ]
机构
[1] Korea Univ, Anam Hosp, Dept Internal Med, Coll Med, Seoul 02841, South Korea
[2] Korea Univ, Dept Biostat, Coll Med, Seoul 02841, South Korea
关键词
myelofibrosis; ruxolitinib; National Health Insurance; propensity score; prognosis; POST-ESSENTIAL THROMBOCYTHEMIA; AVAILABLE THERAPY; POLYCYTHEMIA-VERA; COMFORT-II; SURVIVAL; PHASE-3; SAFETY;
D O I
10.3390/jcm10204774
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In total, 1199 patients diagnosed with MF from January 2011 to December 2017 were identified, of which 731 were included in this study. Patients who received ruxolitinib (n = 224) were matched with those who did not receive the drug (n = 507) using the 1:1 greedy algorithm. Propensity scores were formulated using five variables: age, sex, previous history of arterial/venous thrombosis, and red blood cell (RBC) or platelet (PLT) transfusion dependence at the time of diagnosis. Cox regression analysis for overall survival (OS) revealed that ruxolitinib treatment (hazard ratio (HR), 0.67; p = 0.017) was significantly related to superior survival. In the multivariable analysis for OS, older age (HR, 1.07; p < 0.001), male sex (HR, 1.94; p = 0.021), and RBC (HR, 3.72; p < 0.001) or PLT (HR, 9.58; p = 0.001) transfusion dependence were significantly associated with poor survival, although type of MF did not significantly affect survival. Considering evidence supporting these results remains weak, further studies on the efficacy of ruxolitinib in other populations are needed.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
    Lee, Byung-Hyun
    Moon, Hyemi
    Kang, Ka-Won
    Kim, Byung Soo
    Park, Yong
    [J]. BLOOD, 2019, 134
  • [2] Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway
    Schain, Frida
    Vago, Emese
    Song, Ci
    He, Jianming
    Liwing, Johan
    Lofgren, Christina
    Bjorkholm, Magnus
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (06) : 614 - 619
  • [3] A Population-Based Study on Survival of 652 Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in Italy
    Mora, Barbara
    Pellegrini, Giacomo
    Franchi, Matteo
    Leoni, Olivia
    D'Ippoliti, Daniela
    Di Fabrizio, Valeria
    Gemmi, Fabrizio
    Szasz, Claudia
    Maffioli, Margherita
    Gurnari, Carmelo
    Attardi, Enrico
    Corrao, Giovanni
    Guglielmelli, Paola
    Voso, Maria Teresa
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    [J]. BLOOD, 2023, 142
  • [4] A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region
    Mora, Barbara
    Pellegrini, Giacomo
    Franchi, Matteo
    Maffioli, Margherita
    Brociner, Marco
    Guglielmelli, Paola
    Voso, Maria Teresa
    Ottone, Tiziana
    Ubezio, Marta
    Maggioni, Giulia
    Merli, Michele
    Vannucchi, Alessandro M.
    Della Porta, Matteo G.
    Corrao, Giovanni
    Passamonti, Francesco
    [J]. BLOOD, 2022, 140 : 9737 - 9739
  • [5] Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population-based study
    Kim, Bo Ri
    Yang, Seungkeol
    Choi, Jee Woong
    Choi, Chong Won
    Youn, Sang Woong
    [J]. JOURNAL OF DERMATOLOGY, 2018, 45 (01): : 10 - 16
  • [6] Risk of uveitis in patients with psoriasis in Korea: A nationwide population-based cohort study
    Kim, Bo Ri
    Choi, Seung Woo
    Choi, Chong Won
    Lee, Kun Hee
    Kim, Min Jae
    Woo, Se Joon
    Youn, Sang Woong
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (07) : 1336 - 1343
  • [7] Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
    Verstovsek, S.
    Atallah, E.
    Mascarenhas, J.
    Sun, H.
    Montgomery, M.
    Gupta, V.
    Mesa, R.
    Gotlib, J.
    [J]. LEUKEMIA, 2016, 30 (06) : 1413 - 1415
  • [8] Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
    S Verstovsek
    E Atallah
    J Mascarenhas
    H Sun
    M Montgomery
    V Gupta
    R Mesa
    J Gotlib
    [J]. Leukemia, 2016, 30 : 1413 - 1415
  • [9] Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: a nationwide population-based cohort study in South Korea
    Bong, Jun Woo
    Ju, Yeonuk
    Seo, Jihyun
    Lee, Jung Ae
    Kang, Sang Hee
    Lee, Sun Il
    Min, Byung Wook
    [J]. ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2021, 100 (05) : 282 - 290
  • [10] CURRENT STATUS OF HYPERTENSION IN KOREA: A NATIONWIDE POPULATION-BASED STUDY
    Kim, Hyeon Chang
    Lee, Hokyou
    Lee, Hyeok-Hee
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 : E105 - E105